このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Moberg Pharma 将来の成長

Future 基準チェック /26

Moberg Pharmaは、85.5%と98.2%でそれぞれ年率85.5%で利益と収益が成長すると予測される一方、EPSはgrowで82.6%年率。

主要情報

85.5%

収益成長率

82.6%

EPS成長率

Pharmaceuticals 収益成長	65.1%
収益成長率	98.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Aug 2024

今後の成長に関する最新情報

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

業績と収益の成長予測

OM:MOB - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	101	7	8	21	1
12/31/2025	44	-7	-5	19	1
12/31/2024	9	-22	-84	-25	1
6/30/2024	5	-23	-134	-33	N/A
3/31/2024	1	-23	-139	-31	N/A
12/31/2023	N/A	-21	-157	-33	N/A
9/30/2023	N/A	-18	-133	-29	N/A
6/30/2023	0	-16	-105	-21	N/A
3/31/2023	0	-16	-96	-16	N/A
12/31/2022	0	-16	-85	-17	N/A
9/30/2022	0	-17	-75	-14	N/A
6/30/2022	N/A	-16	-70	-12	N/A
3/31/2022	N/A	-16	-56	-7	N/A
12/31/2021	N/A	-16	-47	-15	N/A
9/30/2021	34	8	-44	-9	N/A
6/30/2021	34	7	-46	-12	N/A
3/31/2021	34	5	-58	-16	N/A
12/31/2020	34	7	-52	-10	N/A
6/30/2020	50	20	-47	4	N/A
6/30/2019	31	-8	-140	-76	N/A
3/31/2019	455	31	15	88	N/A
12/31/2018	5	-28	-10	74	N/A
9/30/2018	341	9	-2	87	N/A
6/30/2018	340	19	85	109	N/A
3/31/2018	334	6	N/A	68	N/A
12/31/2017	439	11	N/A	54	N/A
9/30/2017	438	-1	N/A	30	N/A
6/30/2017	434	0	N/A	-44	N/A
3/31/2017	369	35	N/A	-17	N/A
12/31/2016	334	33	N/A	-18	N/A
9/30/2016	299	36	N/A	-21	N/A
6/30/2016	261	32	N/A	12	N/A
3/31/2016	282	9	N/A	32	N/A
12/31/2015	286	26	N/A	31	N/A
9/30/2015	276	25	N/A	34	N/A
6/30/2015	260	20	N/A	30	N/A
3/31/2015	226	19	N/A	14	N/A
12/31/2014	200	12	N/A	16	N/A
9/30/2014	193	12	N/A	11	N/A
6/30/2014	179	4	N/A	1	N/A
3/31/2014	167	-5	N/A	-6	N/A
12/31/2013	157	-11	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MOB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MOB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MOB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MOBの収益 ( 98.3% ) Swedish市場 ( 1.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: MOBの収益 ( 98.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MOBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Moberg Pharma 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 26% to kr29.00

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

New minor risk - Market cap size

Now 64% undervalued after recent price drop

Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail Fungus

Price target increased by 26% to kr29.00

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Now 22% undervalued

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure

New major risk - Share price stability

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Moberg Pharma Announces Leadership Changes

Moberg Pharma AB (publ) Appoints Nomination Committee

Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America

New major risk - Shareholder dilution

Moberg Pharma AB (publ) Announces National Approval for MOB-015 in Sweden

Moberg Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults

Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European Union

New major risk - Market cap size

Moberg Pharma AB (Publ) Recommends for Approval in EU

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board Members

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Less than half of directors are independent

Moberg Pharma AB (publ) Appoints Anders Bröijersén as Chief Medical Officer and a Member of the Management Team

Moberg Pharma AB (publ), Annual General Meeting, May 16, 2023

Moberg Pharma AB (publ) Approves Board Appointments

Peter Wolpert and Fredrik Granström Step-Down from the Board

Moberg Pharma AB (Publ) Begins Patient Enrollment in North American Phase 3 Study

Moberg Pharma AB Announces Peter Wolpert and Fredrik Granström are Not Available for Re-Election

The Medical Products Agency in Sweden Will Be Reference Member State for Moberg Pharma's European Registration Application

Moberg Pharma AB Announces the Results from the North American Phase 3-Study with MOB-015 (topical terbinafine) for the Treatment of Onychomycosis

Moberg Pharma AB's Paid Subscription Units to Be Delisted

New 90-day low: kr6.40

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

New 90-day low: kr9.05

Market pulls back on stock over the past week

Moberg Pharma AB (publ) to Report Q1, 2021 Results on May 11, 2021

Moberg Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 09, 2021

Moberg Pharma AB (Publ) Appoints Nomination Committee

Moberg Pharma AB (publ), Annual General Meeting, May 18, 2021

New 90-day low: kr11.30

New 90-day low: kr13.52

Caret Pharma LLC entered into an agreement to acquire the assets of Fiber Choice® from Moberg Pharma AB (publ) (OM:MOB) for $6.7 million.

Moberg Pharma AB (publ)(OM:MOB) dropped from S&P Global BMI Index

New 90-day low - kr14.01

Earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘